Compare AVA & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVA | FOLD |
|---|---|---|
| Founded | 1889 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 4.4B |
| IPO Year | N/A | 2007 |
| Metric | AVA | FOLD |
|---|---|---|
| Price | $39.16 | $14.28 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $39.50 | $27.56 |
| AVG Volume (30 Days) | 801.1K | ★ 20.1M |
| Earning Date | 02-25-2026 | 02-18-2026 |
| Dividend Yield | ★ 5.03% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.35 | N/A |
| Revenue | ★ $1,964,000,000.00 | $598,704,000.00 |
| Revenue This Year | $1.44 | $21.49 |
| Revenue Next Year | N/A | $18.42 |
| P/E Ratio | $16.58 | ★ N/A |
| Revenue Growth | 2.14 | ★ 21.28 |
| 52 Week Low | $34.80 | $5.51 |
| 52 Week High | $43.09 | $14.36 |
| Indicator | AVA | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 52.89 | 89.90 |
| Support Level | $38.08 | $14.21 |
| Resistance Level | $38.82 | $14.35 |
| Average True Range (ATR) | 0.51 | 0.08 |
| MACD | 0.11 | -0.01 |
| Stochastic Oscillator | 73.80 | 97.72 |
Avista Corp is an electric and natural gas utility company. The company has two business segments including Avista Utilities, which provides electric distribution and transmission, and natural gas distribution services in parts of eastern Washington and northern Idaho, and also provides natural gas distribution service in parts of northeastern and southwestern Oregon. Avista Utilities has electric generating facilities in Washington, Idaho, Oregon, and Montana. AEL&P is a regulated utility providing electric services in Juneau, Alaska that is a wholly-owned subsidiary and the primary operating subsidiary of AERC.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.